click on circles to display study description...
celecoxib plus endocrine therapy (n=-9) vs. endocrine therapy (n=-9)
randomized controlled trial
celecoxib plus endocrine therapy
celecoxib: PO 400mg/day for 2yr
placebo plus endocrine therapy
la/mBC - HR-positive - 2nd line (L2)
Exclusion criteria: HER2-positive
double blind
160 centers across the UK and Germany
P3 / DFS at 2-sided at 0.05 for 10yr t first, but interim data by the IDMC, it became apparent that the incidence of DFS events in the control group was lower than anticipated. The IDMC therefore recommended in January 2016 that analysis should be performed at a median follow-up of 5yr
powered by vis.js Network